Skip to main content
. 2024 Jan 18;30(3):772–784. doi: 10.1038/s41591-023-02785-8

Table 2.

List of adverse reactions

Adverse reactions Grade Adverse reactions Grade
I–II III IV I–II III IV
CRS 1 0 0 Constitutional
Graft-versus-host disease 0 0 0 Anorexia 1 0 0
Neurological toxicity 0 0 0 Asthenia 12 1 0
Hematological toxicity Fever/chillsa 2 0 0
Neutropenia 3 5 29 Insomnia 2 0 0
Lymphopenia 0 0 37 Somnolence 0 1 0
Thrombocytopenia 23 4 6 Gastrointestinal
Anemia 19 18 0 Diarrhea 4 0 0
Petechia/other bleeding 1 0 0 Hemorrhoids 3 0 0
Laboratory values Ileus 0 2 0
Elevated creatinine 4 0 0 Mucositis 4 0 0
Elevated LFTs 9 1 0 Nausea/vomiting 8 0 0
Elevated CRP 2 0 0 Cardiovascular
Elevated ferritin 5 0 0 Chest pain 2 0 0
Hyperglycemia 1 0 0 Dysrhythmia 7 0 0
Elevated LDH 3 0 0 Hypertension 1 0 0
Hypomagnesemia 1 0 0 Hypotension 5 0 0
Respiratory Edema/fluid overload 2 1 0
Dyspnea 1 0 0 Miscellaneous
Pleural effusion 0 1 0 Anxiety 3 0 0
Pneumonitis 1 1 0 Headache/dizziness 2 0 0
Infection Muscle/bone pain 4 0 0
Bacterial infection 3 1 0 Paresthesia 4 0 0
Viral infection 4 3 0 Rash/skin discoloration 4 0 0
Febrile neutropeniab 0 4 0 Other 2 0 0

LFT, liver function test; CRP, C-reactive protein; LDH, lactate dehydrogenase.

The table includes all side effects from the time of infusion until day +40, irrespective of their attribution to the CAR19/IL-15 NK cell therapy. Abnormalities due to the original disease were not captured.

aOne patient had isolated chills; one patient had fever and was classified as CRS corresponding to the reported CRS case.

bOne patient had fever related to MRSA pneumonia; one patient had a fever that resolved within 24 h of starting antibiotics; one patient had two neutropenic fever episodes (the first episode occurred before the cells were given and the second episode was a recurrence of this fever and did not fit criteria for CRS).